Agilon Health (NYSE:AGL) Issues Quarterly Earnings Results, Beats Estimates By $0.90 EPS

Agilon Health (NYSE:AGL) announced its earnings results on Wednesday. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.90, FiscalAI reports. Agilon Health had a negative return on equity of 146.03% and a negative net margin of 6.09%.The company had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.45 billion.

Here are the key takeaways from Agilon Health’s conference call:

• Q2 results materially exceeded guidance, with revenue of approximately $1.5 billion, medical margin of $197 million and adjusted EBITDA of $70 million, versus a $53 million medical-margin loss and an $83 million EBITDA loss a year earlier.
• Agilon raised its full-year 2026 outlook to approximately $5.8 billion of revenue, $485 million of medical margin and $85 million of adjusted EBITDA, reflecting stronger risk-adjustment revenue, favorable prior-period development and improved cost trends.
• Medical cost trends improved, with 2025 trend revised to 5.8% from 6.2% and Q1 2026 trend moving into the low-6% range; management also cited early benefits from clinical programs, including heart-failure interventions that reduced inpatient first-diagnosis rates from about 25% to below 5%.
• Enhanced data coverage now includes more than 80% of payers and helped lift estimated 2026 risk-adjustment growth to approximately 3% net of the V28 impact, while clinical pathways, AI tools and the burden-of-illness program are improving diagnosis and care management.
• Medicare Advantage membership fell to 437,000 from 498,000 a year ago as the company prioritized profitability over growth. Management expects 2027 growth primarily from existing markets, care-coordination members moving to full risk and ACO opportunities, while remaining disciplined on new-market expansion and payer contracting.

Agilon Health Trading Up 12.4%

AGL stock opened at $106.55 on Thursday. Agilon Health has a 52-week low of $7.48 and a 52-week high of $133.04. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.78 billion, a P/E ratio of -4.94 and a beta of 3.01. The company’s 50-day simple moving average is $106.78 and its 200-day simple moving average is $55.26.

Agilon Health News Summary

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Q2 earnings substantially exceeded expectations. Agilon reported adjusted earnings of $1.04 per share for the quarter ended June 30, compared with analyst estimates ranging from $0.06 to $0.14 and a loss of $6.25 per share a year earlier. Agilon Health Q2 earnings article
• Positive Sentiment: Revenue also topped Wall Street forecasts. Quarterly revenue was $1.49 billion, ahead of the $1.45 billion consensus estimate, indicating better-than-expected business performance. Agilon Health earnings report
• Positive Sentiment: Management increased full-year 2026 guidance. Agilon raised its outlook for total revenue, medical margin and adjusted EBITDA, signaling confidence that its strategic initiatives and operating improvements are gaining traction. Agilon Health reports second-quarter 2026 results
• Neutral Sentiment: Investors will focus on underlying operating metrics. Additional analysis is examining medical margins, membership and other key measures against estimates and year-ago levels to determine whether the earnings beat reflects durable improvement. Agilon key metrics analysis
• Negative Sentiment: Profitability risks remain. Despite the quarterly EPS beat, Agilon continues to report a negative net margin and negative return on equity, while analysts still expect a loss for the full 2026 year. These factors could limit the stock’s upside if future results do not sustain the improvement.

Hedge Funds Weigh In On Agilon Health

A number of large investors have recently bought and sold shares of the business. LPL Financial LLC boosted its position in Agilon Health by 213.4% during the fourth quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock worth $30,000 after purchasing an additional 30,000 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Agilon Health in the third quarter valued at approximately $34,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Agilon Health during the 4th quarter worth approximately $53,000. Tower Research Capital LLC TRC raised its stake in shares of Agilon Health by 214.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock worth $85,000 after buying an additional 25,270 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Agilon Health during the 4th quarter valued at approximately $86,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AGL. Wells Fargo & Company restated an “overweight” rating and set a $141.00 price target (up from $72.00) on shares of Agilon Health in a research note on Monday, July 13th. Citigroup downgraded shares of Agilon Health from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $80.00 to $105.00 in a research note on Thursday, July 23rd. Barclays raised shares of Agilon Health from an “underweight” rating to an “equal weight” rating and set a $81.00 price objective on the stock in a report on Tuesday, May 26th. Deutsche Bank Aktiengesellschaft raised Agilon Health from a “hold” rating to a “buy” rating and upped their target price for the company from $33.00 to $49.00 in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded Agilon Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $66.50.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.